An Australian-led study suggests dietary intake and nutrition are being ignored in global studies of GLP-1s, which could result in malnutrition, even scurvy.

It’s boom times for meal-replacement products that cater to the overwhelmed (and wellness-obsessed) millennial. But Soylent they are not.

Just under €212m was spent on Ozempic and Saxenda under the medical card, Drugs Payment Scheme and Long-Term Illness schemes ...

Six pharmaceutical companies have applied to make a generic version of semaglutide, and competition will continue to heat up ...

Ashwagandha is a small shrub that's having a big moment. Used in traditional Indian medicine for thousands of years, ...

THE HSE has splashed out over €200million on weight-loss jabs in less than three years. And it’s emerged that 80,000 patients ...

Just under €212m was spent on Ozempic and Saxenda under the medical card, Drugs Payment Scheme and Long-Term Illness schemes in two years and eight months ...

Ozempic isn’t the only drug that mimics the natural GLP-1 hormone, so users feel fuller for longer and eat less. There’s also ...

Patient leaflets on weight-loss injections state that gallstones are a "common" side effect, and in medical trials the injections also sometimes led to inflammation of the gallbladder. For example in ...

Insurers cite unsustainable costs as GLP-1 benefits disappear, accelerating a national shift in employer-sponsored ...

Another advantage is that gabapentin does not suppress breathing the way opioids do when taken alone, often making it a safer ...

Department of Health says prescription-only injections can only be sold in pharmacies under supervision of registered ...